J
Jean Sibilia
Researcher at University of Strasbourg
Publications - 582
Citations - 27231
Jean Sibilia is an academic researcher from University of Strasbourg. The author has contributed to research in topics: Rheumatoid arthritis & Medicine. The author has an hindex of 86, co-authored 542 publications receiving 23940 citations. Previous affiliations of Jean Sibilia include University of Paris-Sud & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study.
Eric Hachulla,Virginie Gressin,Loïc Guillevin,Patrick H. Carpentier,Elisabeth Diot,Jean Sibilia,André Kahan,Jean Cabane,Camille Francès,David Launay,Luc Mouthon,Yannick Allanore,Kiet Tiev,Pierre Clerson,Pascal de Groote,Marc Humbert +15 more
TL;DR: This screening algorithm, based on dyspnea, Doppler echocardiographic evaluation of VTR, and RHC, enabled early detection of PAH at a mild stage and whether this early diagnosis translates into improved prognosis for patients with mild PAH will be evaluated in the ongoing 3-year followup.
Journal ArticleDOI
Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren’s syndrome
Jacques-Eric Gottenberg,Nicolas Cagnard,Carlo Lucchesi,Franck Letourneur,Sylvie Mistou,Thierry Lazure,Sébastien Jacques,Nathalie Ba,Marc Ittah,Christine Lepajolec,Marc Labetoulle,M. Ardizzone,Jean Sibilia,Catherine Fournier,Gilles Chiocchia,Xavier Mariette +15 more
TL;DR: The results support the pathogenic interaction between the innate and adaptive immune system in pSS, and the persistence of the IFN signature might be related to a vicious circle, in which the environment interacts with genetic factors to drive the stimulation of salivary TLRs.
Journal ArticleDOI
Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept - Twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial
Joel M. Kremer,Maxime Dougados,P. Emery,Patrick Durez,Jean Sibilia,William Shergy,Serge Steinfeld,Elizabeth A. Tindall,Jean-Claude Becker,Tracy Li,Isaac Nuamah,Richard Aranda,Larry W. Moreland +12 more
TL;DR: Abatacept was associated with significant reductions in disease activity and improvements in physical function that were maintained over the course of 12 months in patients with RA that had remained active despite methotrexate (MTX) therapy.
Journal ArticleDOI
Tolerance and short-term efficacy of rituximab in 43 patients with systemic autoimmune diseases
J.-E. Gottenberg,Loïc Guillevin,Olivier Lambotte,B. Combe,Yannick Allanore,Alain Cantagrel,Claire Larroche,Martin Soubrier,Laurence Bouillet,Maxime Dougados,Olivier Fain,Dominique Farge,X Kyndt,Olivier Lortholary,Charles Masson,B Moura,Philippe Remy,Thierry Thomas,D. Wendling,Juan-Manuel Anaya,Jean Sibilia,Xavier Mariette +21 more
TL;DR: This study showed good tolerance and short term clinical efficacy, with marked corticosteroid reduction in patients with SLE, pSS, vasculitis, and polymyositis, as well as other autoimmune diseases seen in daily rheumatological practice.
Journal ArticleDOI
Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS).
Xavier Mariette,Philippe Ravaud,Serge Steinfeld,Gabriel Baron,Joëlle Goetz,Eric Hachulla,Bernard Combe,Xavier Puéchal,Y.L. Pennec,Bernard Sauvezie,Aleth Perdriger,Gilles Hayem,Anne Janin,Jean Sibilia +13 more
TL;DR: This randomized, double-blind, placebo-controlled study of an anti-TNF agent did not show any evidence of efficacy of infliximab in primary SS.